Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 3.19 Million USD | 126.33% |
| 2021 | -12.14 Million USD | 57.85% |
| 2020 | -28.82 Million USD | 50.48% |
| 2019 | -58.19 Million USD | 57.08% |
| 2018 | -135.61 Million USD | -379.54% |
| 2017 | -28.28 Million USD | -404.55% |
| 2016 | -5.6 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 42.85 Million USD | 84.55% |
| 2023 Q1 | 23.22 Million USD | 626.2% |
| 2023 Q3 | 16.68 Million USD | -61.07% |
| 2022 Q3 | -14.19 Million USD | 61.28% |
| 2022 Q2 | -36.66 Million USD | -326.38% |
| 2022 Q1 | 16.19 Million USD | 233.31% |
| 2022 FY | 3.19 Million USD | 126.33% |
| 2022 Q4 | 3.19 Million USD | 122.53% |
| 2021 Q4 | -12.14 Million USD | 68.99% |
| 2021 Q1 | -83.21 Million USD | -188.74% |
| 2021 Q2 | -66.11 Million USD | 20.55% |
| 2021 FY | -12.14 Million USD | 57.85% |
| 2021 Q3 | -39.16 Million USD | 40.76% |
| 2020 Q4 | -28.82 Million USD | 27.12% |
| 2020 Q2 | -57.59 Million USD | -129.12% |
| 2020 FY | -28.82 Million USD | 50.48% |
| 2020 Q1 | -25.13 Million USD | 56.81% |
| 2020 Q3 | -39.54 Million USD | 31.34% |
| 2019 Q2 | -98.61 Million USD | 17.12% |
| 2019 FY | -58.19 Million USD | 57.08% |
| 2019 Q4 | -58.19 Million USD | 24.92% |
| 2019 Q3 | -77.51 Million USD | 21.4% |
| 2019 Q1 | -118.98 Million USD | 12.26% |
| 2018 Q3 | -65.55 Million USD | 60.06% |
| 2018 FY | -135.61 Million USD | -379.54% |
| 2018 Q4 | -135.61 Million USD | -106.86% |
| 2018 Q2 | -164.14 Million USD | -64.82% |
| 2018 Q1 | -99.59 Million USD | -252.16% |
| 2017 Q1 | 15.53 Thousand USD | 0.0% |
| 2017 Q4 | -28.28 Million USD | 0.0% |
| 2017 FY | -28.28 Million USD | -404.55% |
| 2016 FY | -5.6 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -76.089% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 183.827% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -155.024% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 90.073% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 440.575% |
| Better Therapeutics, Inc. | -860 Thousand USD | 471.86% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 113.445% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -873.691% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 30.022% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 154.92% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | -0.989% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 36.066% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 97.614% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -1685.096% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 74.081% |
| Molecular Templates, Inc. | 707 Thousand USD | -352.334% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -629.398% |
| NexImmune, Inc. | -3.13 Million USD | 202.054% |
| Orgenesis Inc. | 21.78 Million USD | 85.32% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -22.248% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 642268.675% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 167.889% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 2667.128% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 97.116% |
| Statera Biopharma, Inc. | 14.41 Million USD | 77.817% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 142.101% |
| Trevena, Inc. | 2.25 Million USD | -41.63% |
| Vaxxinity, Inc. | 10.13 Million USD | 68.437% |
| Vaccinex, Inc. | -1.28 Million USD | 348.292% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -828.447% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 75.844% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -4344.012% |